Cargando…

Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease

INTRODUCTION: Amyloid, Tau, and neurodegeneration biomarkers can stage Alzheimer's Disease (AD). Synaptic biomarkers may help track cognition. METHODS: In cognitively normal controls, Mild Cognitive Impairment (MCI) and AD, we investigated CSF biomarkers in relation to cognitive measures and as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galasko, Douglas, Xiao, Meifang, Xu, Desheng, Smirnov, Denis, Salmon, David P., Dewit, Nele, Vanbrabant, Jeroen, Jacobs, Dirk, Vanderstichele, Hugo, Vanmechelen, Eugeen, Worley, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911971/ https://www.ncbi.nlm.nih.gov/pubmed/31853477 http://dx.doi.org/10.1016/j.trci.2019.11.002

Ejemplares similares

Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study
por: Edmonds, Emily C., et al.
Publicado: (2017)

Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia
por: Das, Shreyasee, et al.
Publicado: (2023)

Potential sources of interference on Abeta immunoassays in biological samples
por: Vanderstichele, Hugo, et al.
Publicado: (2012)

Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
por: Vanderstichele, Hugo Marcel, et al.
Publicado: (2019)

Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum
por: Goossens, Julie, et al.
Publicado: (2023)

CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
por: Mouton-Liger, François, et al.
Publicado: (2020)

Plasma p‐tau181/Aβ(1‐42) ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ(1‐42) and future cognitive decline
por: Fowler, Christopher J., et al.
Publicado: (2022)

P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles
por: Wesenhagen, Kirsten E. J., et al.
Publicado: (2022)

Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer's Disease: A Pilot Study
por: Schipke, Carola G., et al.
Publicado: (2018)

Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging
por: Machulda, Mary M., et al.
Publicado: (2020)

Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease
por: Kirsebom, Bjørn-Eivind, et al.
Publicado: (2018)

A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimer’s Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration
por: Das, Shreyasee, et al.
Publicado: (2022)

Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
por: Kac, Przemysław R., et al.
Publicado: (2022)

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid(42) and DJ-1 in Human Cerebrospinal Fluid
por: Kruse, Niels, et al.
Publicado: (2016)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis
por: Padovani, Alessandro, et al.
Publicado: (2022)

Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
por: De Meyer, Steffi, et al.
Publicado: (2022)

Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM(R) Scale
por: Lehmann, Sylvain, et al.
Publicado: (2018)

An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
por: Van Hulle, Carol, et al.
Publicado: (2020)

Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease
por: Libiger, Ondrej, et al.
Publicado: (2021)

Accelerating drug development for Alzheimer's disease through the use of data standards
por: Neville, Jon, et al.
Publicado: (2017)

Neuropsychological comparison of incident MCI and prevalent MCI
por: Hansen, Allison, et al.
Publicado: (2018)

A role for synaptic plasticity in the adolescent development of executive function
por: Selemon, L D
Publicado: (2013)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
por: Cicognola, Claudia, et al.
Publicado: (2016)

Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor
por: Timmers, Maarten, et al.
Publicado: (2016)

Building a taxonomy of integrated palliative care initiatives: results from a focus group
por: Ewert, Benjamin, et al.
Publicado: (2016)

β-Adrenergic Control of Hippocampal Function: Subserving the Choreography of Synaptic Information Storage and Memory
por: Hagena, Hardy, et al.
Publicado: (2016)

In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET
por: Mecca, Adam P., et al.
Publicado: (2020)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and (18)F-FDG-PET imaging
por: Ottoy, Julie, et al.
Publicado: (2019)

FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort
por: Caminiti, Silvia Paola, et al.
Publicado: (2018)

Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics
por: Varatharajah, Yogatheesan, et al.
Publicado: (2019)

Nurse Executives Impacting the Human Experience in Health Care
por: Mansfield, Jerry Alden, et al.
Publicado: (2022)

Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study
por: Pentz, Rowan, et al.
Publicado: (2020)

Elevated phospholipase D isoform 1 in Alzheimer's disease patients' hippocampus: Relevance to synaptic dysfunction and memory deficits
por: Krishnan, Balaji, et al.
Publicado: (2018)

Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [(11)C]UCB‐J
por: Mecca, Adam P., et al.
Publicado: (2022)

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal
por: Vermunt, Lisa, et al.
Publicado: (2019)

Computer Interactive Reminiscence and Conversation Aid groups—Delivering cognitive stimulation with technology
por: Astell, Arlene J., et al.
Publicado: (2018)

Aiding the discovery of new treatments for dementia by uncovering unknown benefits of existing medications
por: Kern, David M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kkok6144tqo2o7bqdr02k5hhrh